MVA-MUC1-IL2

BIOLOGICAL2 trials

Sponsors

Transgene

Conditions

Carcinoma, Non-Small-Cell LungProstatic Neoplasms

Phase 2

Vaccine Study of MVA-MUC1-IL2 in Patients With Prostate Cancer

TerminatedNCT00040170

TransgeneProstatic Neoplasms

Start: 2002-05-31Target: 50Updated: 2006-11-02

Immunotherapy With TG4010 in Patients With Advanced Non-Small Cell Lung Cancer

CompletedNCT00415818

TransgeneCarcinoma, Non-Small-Cell Lung

Start: 2005-12-31End: 2010-03-31Updated: 2014-07-16

Related Papers

Viral based vaccine TG4010 induces broadening of specific immune response and improves outcome in advanced NSCLC

Journal for ImmunoTherapy of Cancer2017-09-0263 citations

Abstract 2497: Immune checkpoint inhibitors enhance benefits of modified vaccinia virus Ankara to improve survival in preclinical models of cancer

Cancer Research2015-08-011 citations

Abstract 2498: The MVA viral platform for the treatment of cancer and chronic infectious diseases: Clinical experience from four randomized controlled phase II studies

Cancer Research2015-08-01

Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial.

2011-10-21204 citations